In short
Clinical trials are investigating Sulfasalazine in several conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, and acute myeloid leukemia. These studies look at safety, effectiveness, treatment tapering, and disease control in children and adults. The trials include different phases and patient groups.
Key points
- Sulfasalazine is being studied in several clinical trials across different diseases, not just one condition. The source data includes studies in rheumatoid arthritis, psoriatic arthritis, Crohn's disease, and acute myeloid leukemia. Trial phases range from Phase 1 to Phase 3, plus one low-intervention study, so the research includes early safety work and larger comparison studies. The target groups include children with Crohn's disease, adults with inflammatory joint disease, and older adults with leukemia. The main study goals are to measure remission, low disease activity, treatment tapering, endoscopic response, and safety outcomes such as adverse events or dose-limiting toxicity.
Trial overview
The source data includes 7 clinical trials that study Sulfasalazine in different ways, either alone or as part of a treatment plan. These studies are in Phase 1, Phase 2, Phase 3, and one low-intervention design. The trials focus on people with inflammatory joint disease, bowel disease, and leukemia.
Rheumatoid arthritis studies
Several trials study rheumatoid arthritis, which is a long-term disease that causes joint pain, swelling, and stiffness. One Phase 3 study compares active conventional therapy with biologic treatments and also looks at two dose-reduction strategies in people who respond to treatment. Its main outcomes are remission at week 24, joint damage seen on x-ray scoring, and remission after the dose is reduced.
Another trial compares targeted therapies with triple therapy that includes Sulfasalazine, methotrexate or leflunomide, and hydroxychloroquine in patients who did not respond well enough to earlier treatment. The main goal is to see whether targeted therapy gives better low disease activity while keeping steroid use low. A Phase 2 proof-of-concept study also includes Sulfasalazine in a group of adults with active rheumatoid arthritis despite prior advanced therapies, and it measures change in DAS28-CRP at Week 12.
A newer Phase 3 study in rheumatoid arthritis compares a tailor-made treatment approach with routine care and uses patient features such as autoantibodies and response to glucocorticoids and JAK inhibitors to guide treatment choices. Its main outcomes include how many patients need biologic or targeted synthetic DMARDs after 10 months and how disease activity changes over time, plus cost-effectiveness measured by ICER.
Psoriatic arthritis study
One Phase 3 study looks at psoriatic arthritis, which is arthritis linked to psoriasis, a skin disease. The study tests how far immunosuppressive medication can be tapered without symptoms coming back in adults who already have stable minimal disease activity. The main outcomes are whether minimal disease activity is still present after 12 months and the PASDAS score at month 12.
Sulfasalazine is one of the medicines listed in the tapering study, which means it may be part of the treatment being reduced or adjusted. This kind of study helps researchers understand which patients can safely use less medicine while staying well controlled.
Crohn's disease study
One Phase 3 pediatric study investigates Crohn's disease, which is a type of inflammatory bowel disease that can cause belly pain, diarrhea, and poor growth in children. The study is in children with moderately to severely active disease and evaluates upadacitinib, while Sulfasalazine appears in the intervention list as a treatment used in the study setting.
The main outcomes are clinical remission by the Pediatric Crohn's Disease Activity Index, endoscopic response, and the number of adverse events. The brief summary shows that the study is meant to compare remission and endoscopic response at Week 64 in a group of pediatric participants who first achieved clinical response at Week 12.
Acute myeloid leukemia study
One Phase 1 study examines acute myeloid leukemia, a fast-growing blood cancer, in older adults with newly diagnosed non-favorable disease. In this study, Sulfasalazine is added to chemotherapy with cytarabine and idarubicin to test the safety of the combination.
The Phase 1 part focuses on dose-limiting toxicity and finding the maximal tolerated dose, which is the highest dose that can be given with acceptable safety. The Phase 2 part looks at MRD-negative complete response at the end of induction, which means a complete response with no minimal residual disease detected by the study criteria.
What the outcomes mean for patients
Many of the trials use outcomes related to disease activity, which means how active the illness is at a given time. In rheumatoid arthritis, this may be measured by DAS28-CRP, CDAI, or DAS over time. In Crohn's disease, researchers use PCDAI and endoscopy results, while in psoriatic arthritis they use MDA and PASDAS.
Safety is also important in these studies. Some trials count adverse events, and the leukemia study specifically tracks dose-limiting toxicity during dose escalation. Together, these trials show that researchers are studying whether Sulfasalazine can be part of effective treatment plans across several diseases and patient groups.